Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.
Dettling
M
M
Cascorbi
I
I
Roots
I
I
Mueller-Oerlinghausen
B
B
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000235:genetics*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006683:HLA-DQ Antigens / Q000235:genetics; D059866:HLA-DQ beta-Chains; D006684:HLA-DR Antigens / Q000235:genetics; D059845:HLA-DRB4 Chains; D006650:Histocompatibility Testing; D006801:Humans; D007585:Jews / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D012559:Schizophrenia / Q000188:drug therapy*; D044465:White People / Q000235:genetics*
D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C057615:HLA-DQbeta antigen; D006684:HLA-DR Antigens; D059845:HLA-DRB4 Chains; D003024:Clozapine